Anzeige
Mehr »
Donnerstag, 12.02.2026 - Börsentäglich über 12.000 News
Top-Ergebnisse: 1,75 g/t Gold über 30,4 Meter + massives Tagebau-Potenzial
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D2TK | ISIN: CH1216478797 | Ticker-Symbol: ZX6
Tradegate
12.02.26 | 19:22
63,48 Euro
-8,58 % -5,96
1-Jahres-Chart
DSM-FIRMENICH AG Chart 1 Jahr
5-Tage-Chart
DSM-FIRMENICH AG 5-Tage-Chart
RealtimeGeldBriefZeit
63,2263,6619:43
63,2863,6019:43
GlobeNewswire (Europe)
690 Leser
Artikel bewerten:
(2)

dsm-firmenich shareholders approve all resolutions at Annual General Meeting 2025

Press Release

dsm-firmenich shareholders approve all resolutions at Annual General Meeting 2025

Kaiseraugst (Switzerland), Maastricht (Netherlands), May 6, 2025

dsm-firmenich, innovators in nutrition, health, and beauty, announces that its shareholders approved all proposals of the Board of Directors at its Annual General Meeting today, including the Management Report, the consolidated financial statements as well as the Sustainability Report 2024.

Key highlights include:

  • Thomas Leysen was re-elected and confirmed as Chairman of the Board.
  • Patrick Firmenich, Sze Cotte-Tan, Antoine Firmenich, Erica Mann, Carla Mahieu, Frits van Paasschen, André Pometta, John Ramsay, Richard Ridinger, and Corien Wortmann were re-elected to the board.
  • Shareholders approved the dividend of €2.50 per share. The dividend will be paid as of May 16, 2025, and the last trading day with entitlement to receive the payment is May 7, 2025.
  • Shareholders approved a maximum total amount of remuneration of €3,682,582 for the Board of Directors for the year through the 2026 AGM.
  • Shareholders approved a maximum total amount of remuneration of €43,982,072 for the Executive Committee for the financial year 2026.
  • Shareholders also endorsed the 2024 Compensation Report in a consultative vote.
  • Carla Mahieu, Thomas Leysen, Frits van Paasschen, and André Pometta were re-elected to the Compensation Committee. The Board intends to appoint Carla Mahieu as Chair of the committee.
  • PricewaterhouseCoopers AG was elected as auditor.
  • Christian Hochstrasser was re-elected as the independent proxy.
  • An amendment to the capital band provision in the Articles of Association allowing the Board of Directors to decrease the share capital one or several times within the limit of 90% of the current share capital. This authorization will be used to reduce the capital following the implementation of dsm-firmenich's share buyback program announced on February 13, 2025.

The shareholders in attendance, together with the votes represented by independent proxy, represented 72.72% of shares.

PDF version of this press release can be found here.

About dsm-firmenich
As innovators in nutrition, health, and beauty, dsm-firmenich reinvents, manufactures, and combines vital nutrients, flavors, and fragrances for the world's growing population to thrive. With our comprehensive range of solutions, with natural and renewable ingredients and renowned science and technology capabilities, we work to create what is essential for life, desirable for consumers, and more sustainable for the planet. dsm-firmenich is a Swiss company with dual headquarters in Kaiseraugst, Switzerland and Maastricht, Netherlands, listed on the Euronext Amsterdam, with operations in almost 60 countries and revenues of more than €12 billion. With a diverse, worldwide team of nearly 30,000 employees, we bring progress to life every day, everywhere, for billions of people. www.dsm-firmenich.com

For more information

Media relations
Robin Roothans
tel. +41
Investor relations
Dave Huizing
tel. +31

Forward-looking statements
This press release may contain forward-looking statements with respect to dsm-firmenich's future performance and position. Such statements are based on current expectations, estimates and projections of dsm-firmenich and information currently available to the company. dsm-firmenich cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance, transaction progress and positions to differ materially from these statements. dsm-firmenich has no obligation to update the statements contained in this press release, unless required by law. This communication contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. The English language version of this press release prevails over other language versions.

Attachment

  • Press release_dsm shareholders approve all resolutions at Annual General Meeting 2025_20250506_FINAL (https://ml-eu.globenewswire.com/Resource/Download/471fbe4d-2454-4c01-9494-c30d45bbb0fb)

© 2025 GlobeNewswire (Europe)
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.